Los Angeles Capital Management’s Regenxbio RGNX Stock Holding History

Los Angeles Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$117K	Sell	13,959 -20,095	-59%	-$211K	﹤0.01%	1295
2025 Q4	$437K	Sell	34,054 -58,568	-63%	-$730K	﹤0.01%	946
2025 Q3	$894K	Sell	92,622 -32,786	-26%	-$290K	﹤0.01%	736
2025 Q2	$1.03M	Buy	+125,408	New	+$1.05M	﹤0.01%	630
2023 Q2	–	Sell	-19,479	Closed	-$368K	–	1269
2023 Q1	$368K	Sell	19,479 -14,781	-43%	-$327K	﹤0.01%	951
2022 Q4	$777K	Sell	34,260 -2,678	-7%	-$60.5K	﹤0.01%	775
2022 Q3	$976K	Sell	36,938 -23,982	-39%	-$711K	0.01%	706
2022 Q2	$1.5M	Buy	60,920 +32,680	+116%	+$816K	0.01%	602
2022 Q1	$937K	Buy	+28,240	New	+$784K	﹤0.01%	788
2019 Q4	–	Sell	-21,787	Closed	-$776K	–	1335
2019 Q3	$776K	Sell	21,787 -5	-0%	-$203	﹤0.01%	873
2019 Q2	$1.12M	Hold	21,792	–	–	0.01%	810
2019 Q1	$1.25M	Buy	21,792 +10,600	+95%	+$525K	0.01%	783
2018 Q4	$470K	Buy	11,192 +225	+2%	+$13.2K	﹤0.01%	980
2018 Q3	$828K	Buy	10,967 +5,120	+88%	+$369K	﹤0.01%	948
2018 Q2	$420K	Buy	+5,847	New	+$279K	﹤0.01%	1187

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's RGNX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Regenxbio (RGNX) stake by 59% in Q1 2026, selling an estimated $211K and leaving 13,959 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1295.

Los Angeles Capital Management first reported a position in RGNX in Q2 2018 and has held it in 15 quarters since. The position peaked at $1.5M in Q2 2022. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Los Angeles Capital Management held 13,959 shares of Regenxbio worth $117K as of Q1 2026.
Los Angeles Capital Management sold 20,095 Regenxbio shares in Q1 2026, an estimated $211K.
Regenxbio made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1295 holding.
Los Angeles Capital Management first reported a position in Regenxbio in Q2 2018 and has held it in 15 quarters since.
Los Angeles Capital Management's Regenxbio position peaked at $1.5M in Q2 2022.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.